GeoVax Labs, Inc. (OTCQB: GOVX)
Market Cap: $3,086,399
Outstanding Shares: 56,218,567
GeoVax Labs, Inc. ( OTCQB : GOVX ), a biotechnology company developing human vaccines, announced today it has received a Notice of Award from the National Institute of Allergy and Infectious Disease (NIAID), part of the U.S. National Institutes of Health (NIH), for a Phase II Small Business Innovative Research (SBIR) grant in support of its HIV vaccine development program. The grant award of $658,159 will fund the second year of a two-year project period with a total budget of $1,398,615.
The grant, entitled “Enhancing Protective Antibody Responses for a DNA/MVA HIV Vaccine“, supports preclinical studies in non-human primates (NHP) evaluating the immunogenicity and protective efficacy of the GeoVax Clade B HIV preventive vaccine (GOVX-B11) with or without a bivalent (two component) protein boost. Clade B is the subtype of HIV most prevalent in the developed world — primarily the Americas, Western Europe, Australia and Japan.
UPTICK Newswire LLC is not an investment advisor. Investors are strongly encouraged to do their own due diligence and review all company documents and press releases to ensure the company noted above fits their own investment qualifications.
Source: Uptick Newswire